Elanco Animal Health Inc (FRA:5EA)
€ 15.556 -0.1 (-0.64%) Market Cap: 7.71 Bil Enterprise Value: 12.68 Bil PE Ratio: 0 PB Ratio: 1.39 GF Score: 66/100

Elanco Animal Health Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 05:30PM GMT
Release Date Price: €25.4 (-1.55%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott from JPMorgan and very pleased to be introducing Elanco today. From Elanco, we have the company's CEO, Jeff Simmons. If we think back to last year, the company presented shortly after its IPO. We had a very busy 2019, including the Bayer transaction announced over the summer, so very much looking forward to Jeff's comments and as we think about Elanco heading into 2020.

Jeffrey N. Simmons
Elanco Animal Health Incorporated - President, CEO & Director

Thanks, Chris. Look forward to the opportunity to share a little bit of the exciting year we had in 2019 and looking forward in 2020. Of course, I'll make the disclaimer of forward-looking comments. Here's what I'd like to do today. No question an exciting time in our history as a company.

I'd like to cover 3 areas today. First, back to some of the compelling fundamentals of the industry that we're in, a little different than pharmaceuticals that is represented here today,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot